Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD

Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Hannah Choe, Peter Dawson, Andrew C. Harris, Eric van Hooren, Willem Klaassen, Eric Leifer, Margaret L. MacMillan, Ypke van Oosterhout, Lia Perez, Iskra Pusic, Phuong Vo, John E. Levine

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)302-303
Number of pages2
JournalBone marrow transplantation
Volume57
Issue number2
DOIs
StatePublished - Feb 2022

Bibliographical note

Funding Information:
MH: Research Support/Funding: Takeda Pharmaceutical Company; Consultancy: Incyte Corporation; ADC Therapeutics; Pharmacyclics, Omeros, Kite. Speaker’s Bureau: Sanofi Genzyme, AstraZeneca, BeiGene. HA: Consultant and speaker bureau for Incyte, BMS. Research grant from Incyte. IP: Syndax Advisory Board. EvH, WK, and YvO: are employees of Xenikos and own equity in Xenikos. JEL: Research support from Biogen, Incyte, Kamada, and Mesoblast; consulting for Bluebird, Incyte, Jazz, Mesoblast, Omeros, Symbio, Talaris, and X4 Pharmaceuticals; GVHD biomarkers patent and royalties from Viracor.

Funding Information:
The authors wish to acknowledge the support provided by Xenikos and Grant Numbers U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung and Blood Institute and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

PubMed: MeSH publication types

  • Letter

Cite this